Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder?
Cockfield
S M
SM
Department of Medicine, University of Alberta, Edmonton, Canada.
Preiksaitis
J
J
Harvey
E
E
Jones
C
C
Hebert
D
D
Keown
P
P
Halloran
P F
PF
D000367:Age Factors; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000961:Antilymphocyte Serum / Q000008:administration & dosage*; D005260:Female; D004854:Herpesvirus 4, Human; D006801:Humans; D007115:Immunization Schedule; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000379:methods*; D008232:Lymphoproliferative Disorders / Q000209:etiology*; D008297:Male; D016853:Muromonab-CD3; D012189:Retrospective Studies; D012307:Risk Factors; D012737:Sex Factors; D014412:Tumor Virus Infections / Q000150:complications
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D016853:Muromonab-CD3